Population-Attributable Fractions of Personal Comorbidities for Liver, Gallbladder, and Bile Duct Cancers

Background: We aim to estimate population-attributable fractions (PAF) for 13 comorbidities potentially predisposing to hepatobiliary cancer of hepatocellular carcinoma (HCC), gallbladder cancer (GBC), cancers of the intrahepatic and extrahepatic bile ducts (ICC and ECC), and ampullary cancer. Methods: Patients were identified from the Swedish Inpatient Register from 1987 to 2018 and cancers from the Swedish Cancer Registry from 1997 through 2018. PAFs were calculated for each comorbidity-associated cancer using a cohort study design. Results: For male HCC, the major individual comorbidities (PAF > 10) were diabetes, alcohol-related liver disease, and hepatitis C virus infection. For female HCC, diabetes and autoimmune diseases were important contributors. For female GBC, gallstone disease was an overwhelming contributor, with a PAF of 30.57%, which was also important for men. The overall PAF for male ICC was almost two times higher than the female one. For ECC and ampullary cancer, infection of bile ducts was associated with the highest PAF. Conclusions: The 13 comorbidities accounted for 50% or more of the potential etiological pathways of each hepatobiliary cancer except female ICC. The underlying convergent mechanism for these cancers may be chronic inflammation lasting for decades and thus offering possibilities for intervention and disease monitoring.

[1]  K. Hemminki,et al.  Long‐term survival trends in solid cancers in the Nordic countries marking timing of improvements , 2022, International journal of cancer.

[2]  J. Koshiol,et al.  Epidemiologic patterns of biliary tract cancer in the United States: 2001–2015 , 2022, BMC Cancer.

[3]  K. Hemminki,et al.  Personal comorbidities and their subsequent risks for liver, gallbladder and bile duct cancers , 2022, International journal of cancer.

[4]  K. Hemminki,et al.  Survival trends in solid cancers in the Nordic countries through 50 years. , 2022, European journal of cancer.

[5]  K. Hemminki,et al.  Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries , 2022, JHEP reports : innovation in hepatology.

[6]  K. Hemminki,et al.  Long‐term incidence in hepatocellular carcinoma and intrahepatic bile duct cancer in Denmark, Finland, Norway and Sweden, role of Thorotrast? , 2022, International journal of cancer.

[7]  K. Hemminki,et al.  Familial Risks for Liver, Gallbladder and Bile Duct Cancers and for Their Risk Factors in Sweden, a Low-Incidence Country , 2022, Cancers.

[8]  K. Hemminki,et al.  Long‐term incidence and survival trends in cancer of the gallbladder and extrahepatic bile ducts in Denmark, Finland, Norway and Sweden with etiological implications related to Thorotrast , 2022, International journal of cancer.

[9]  Zhe-yu Chen,et al.  Aspirin for the prevention of hepatocellular carcinoma: an updated meta-analysis with particular focus on patients with chronic liver disease , 2022, European Journal of Clinical Pharmacology.

[10]  Myeong Jun Song,et al.  Advancing the global public health agenda for NAFLD: a consensus statement , 2021, Nature Reviews Gastroenterology & Hepatology.

[11]  M. Färkkilä,et al.  Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland , 2021, United European gastroenterology journal.

[12]  A. Gavin,et al.  Comparison of liver cancer incidence and survival by subtypes across seven high‐income countries , 2021, International journal of cancer.

[13]  L. Zender,et al.  The immunological and metabolic landscape in primary and metastatic liver cancer , 2021, Nature Reviews Cancer.

[14]  Darjus F. Tschaharganeh,et al.  Liver Inflammation and Hepatobiliary Cancers. , 2021, Trends in cancer.

[15]  M. Borad,et al.  Aspirin and Statin Use and the Risk of Gallbladder Cancer , 2021, Cancers.

[16]  E. Rigopoulou,et al.  Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases , 2021, Cancers.

[17]  A. Zhu,et al.  Biliary tract cancer , 2021, The Lancet.

[18]  K. Hemminki,et al.  Familial risks between Graves disease and Hashimoto thyroiditis and other autoimmune diseases in the population of Sweden , 2020, Journal of translational autoimmunity.

[19]  Siddharth Singh,et al.  Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis , 2020, Cancers.

[20]  B. Isaksson,et al.  Treatment patterns and survival in patients with hepatocellular carcinoma in the Swedish national registry SweLiv , 2019, BJS open.

[21]  A. Duberg,et al.  Hepatitis C Virus Infection and the Temporal Trends in the Risk of Liver Cancer: A National Register-Based Cohort Study in Sweden , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[22]  C. Thongprayoon,et al.  Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. , 2019, QJM : monthly journal of the Association of Physicians.

[23]  R. Sinha,et al.  Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. , 2019, Journal of the National Cancer Institute.

[24]  Prashanth Rawla,et al.  Epidemiology of gallbladder cancer , 2019, Clinical and experimental hepatology.

[25]  A. Villanueva Hepatocellular Carcinoma. , 2019, The New England journal of medicine.

[26]  C. la Vecchia,et al.  Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors , 2018, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[27]  A. Gavin,et al.  The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015 , 2018, British Journal of Cancer.

[28]  K. Hemminki,et al.  Surveillance Bias in Cancer Risk After Unrelated Medical Conditions: Example Urolithiasis , 2017, Scientific Reports.

[29]  P. Ott,et al.  Time‐trends in incidence and prognosis of hepatocellular carcinoma in Denmark: A nationwide register‐based cohort study , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[30]  D. Whiteman,et al.  The fractions of cancer attributable to modifiable factors: A global review. , 2016, Cancer epidemiology.

[31]  B. Graubard,et al.  Population attributable fractions of risk factors for hepatocellular carcinoma in the United States , 2016, Cancer.

[32]  K. Hemminki,et al.  Cancer risk in patients with type 2 diabetes mellitus and their relatives , 2015, International journal of cancer.

[33]  A. Facciorusso The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives. , 2013, Current diabetes reviews.

[34]  Hayato Nakagawa,et al.  Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. , 2012, World journal of gastroenterology.

[35]  A. Toschke,et al.  An illustration of and programs estimating attributable fractions in large scale surveys considering multiple risk factors , 2009 .

[36]  A. Lindberg,et al.  Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. , 2006, Respiratory medicine.

[37]  J. Zucman‐Rossi,et al.  Hepatocellular carcinoma , 1998, Nature Reviews Disease Primers.

[38]  O S Miettinen,et al.  Proportion of disease caused or prevented by a given exposure, trait or intervention. , 1974, American journal of epidemiology.

[39]  S. Taylor-Robinson,et al.  Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis. , 2019, Journal of hepatology.